VIDEO: HCV retreatment regimen benefited patients who failed therapy
Click Here to Manage Email Alerts
Healio spoke with Nancy S. Reau, MD, FAASLD, AGAF, about a study evaluating a hepatitis C retreatment regimen in patients who failed therapy with Vosevi.
In the study, which was presented at The Liver Meeting Digital Experience, the researchers treated patients with HCV who failed treatment with Vosevi (sofosbuvir/velpatasvir/voxilaprevir, Gilead Sciences) with a regimen of Solvadi (sofosbuvir, Gilead Sciences) plus Mavyret (glecaprevir/pibrentasvir, Abbvie) plus ribavirin for 16 or 24 weeks.
“They had incredibly great efficacy,” Reau, the Richard B. Capps Chair of Hepatology at Rush University in Chicago, said, noting that every treatment failure experienced cure with the retreatment regimen.
Reau also said that the treating physicians initially used higher doses of ribavirin and opted for 24 weeks of treatment, but after observing high cure rates, they were more comfortable with a 16-week course of therapy.
Interestingly, several patients had direct-acting antiviral resistance on testing, according to Reau.
“The authors felt that that might have to do with the delay in when the patients had failed and when the resistance tests were done, as the wild-type does tend to be very fit and sometimes outnumbers the resistance, even though we do assume it’s there in the background setting up a risk for failure if you would not have a good treatment strategy for salvage,” Reau said.
Collapse
Saxena V, et al. Parallel 14: Hepatitis C oral session. Presented at: The Liver Meeting Digital Experience; Nov. 12-15, 2021 (virtual meeting).
Read more about
Click Here to Manage Email Alerts